Announcements
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Completes Enrollment in Phase 4 CATALYST Trial
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
- Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
- Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
- Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
- Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
More ▼
Key statistics
On Friday, Corcept Therapeutics Inc (0I3Q:LSE) closed at 23.91, 14.55% above the 52 week low of 20.88 set on Feb 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 23.91 |
Average volume | 2.00k |
---|---|
Shares outstanding | 103.84m |
Free float | 91.99m |
P/E (TTM) | 22.93 |
Market cap | 2.55bn USD |
EPS (TTM) | 1.07 USD |
Data delayed at least 20 minutes, as of May 03 2024 18:26 BST.
More ▼